Ondine Biomedical Inc.
OBIMF
$0.25
$0.0847.06%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.78% | 35.90% | 16.63% | 10.77% | 49.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.78% | 35.90% | 16.63% | 10.77% | 49.26% |
| Cost of Revenue | 71.03% | 68.68% | 6.72% | 1.31% | 19.80% |
| Gross Profit | 21.07% | 19.43% | 22.81% | 16.67% | 70.32% |
| SG&A Expenses | -21.04% | -22.13% | 1.94% | -3.17% | 51.40% |
| Depreciation & Amortization | -8.31% | -9.65% | 2.52% | -2.68% | -7.40% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.63% | 47.57% | 54.03% | 46.31% | 64.83% |
| Operating Income | -50.84% | -48.76% | -58.14% | -50.21% | -66.61% |
| Income Before Tax | -50.21% | -48.14% | -60.02% | -52.00% | -69.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.21% | -48.14% | -60.02% | -52.00% | -69.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.21% | -48.14% | -60.02% | -52.00% | -69.18% |
| EBIT | -50.84% | -48.76% | -58.14% | -50.21% | -66.61% |
| EBITDA | -51.17% | -48.56% | -56.12% | -48.29% | -67.35% |
| EPS Basic | 6.82% | 7.41% | 11.11% | 15.97% | -10.00% |
| Normalized Basic EPS | 6.10% | 7.14% | 10.96% | 16.00% | -5.13% |
| EPS Diluted | 6.82% | 7.41% | 11.11% | 15.97% | -10.00% |
| Normalized Diluted EPS | 6.10% | 7.14% | 10.96% | 16.00% | -5.13% |
| Average Basic Shares Outstanding | 60.18% | 60.18% | 81.08% | 81.08% | 54.25% |
| Average Diluted Shares Outstanding | 60.18% | 60.18% | 81.08% | 81.08% | 54.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |